Description

DEFRIJET 250 MG

Indications

DEFRIJET 250 MG is primarily indicated for the treatment of iron overload conditions, particularly in patients with chronic anemia due to conditions such as thalassemia, sickle cell disease, or other chronic hemolytic anemias. It is also used in patients who have received multiple blood transfusions, leading to secondary hemochromatosis. DEFRIJET is effective in reducing excess iron in the body, thereby preventing complications associated with iron overload, such as liver damage, heart problems, and diabetes.

Mechanism of Action

DEFRIJET contains the active ingredient Deferasirox, which is a selective iron chelator. The mechanism of action involves binding to excess iron in the bloodstream, forming a stable complex that can be excreted through the gastrointestinal tract. By chelating iron, DEFRIJET reduces the free iron pool in the body, thereby preventing the formation of reactive oxygen species that can lead to oxidative stress and cellular damage. This mechanism is crucial in mitigating the risks associated with iron overload.

Pharmacological Properties

DEFRIJET is administered orally and is well-absorbed in the gastrointestinal tract. It exhibits a high affinity for ferric iron, allowing it to effectively remove excess iron from the body. The pharmacokinetics of DEFRIJET show that peak plasma concentrations are achieved within 1 to 4 hours after administration. The drug has a half-life of approximately 8 to 16 hours, allowing for once-daily dosing. DEFRIJET is primarily metabolized in the liver, and its metabolites are excreted via the feces and urine.

Contraindications

DEFRIJET is contraindicated in patients with known hypersensitivity to Deferasirox or any of its components. It should not be used in patients with severe renal impairment (creatinine clearance less than 40 mL/min) or in those with active hepatic disease. Additionally, DEFRIJET is not recommended for use in patients with a history of gastrointestinal bleeding or peptic ulcer disease, as it may exacerbate these conditions.

Side Effects

The use of DEFRIJET may be associated with several side effects, although not all patients will experience them. Common side effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Other potential adverse effects include skin rashes, elevated liver enzymes, and renal impairment. Rare but serious side effects may include agranulocytosis, thrombocytopenia, and hepatic failure. Patients should be monitored regularly for any signs of these adverse reactions during treatment.

Dosage and Administration

The recommended starting dose of DEFRIJET for adults and children over 6 years of age is typically 20 mg/kg body weight once daily. The dose may be adjusted based on the patient’s response to treatment and the degree of iron overload. It is important to take DEFRIJET on an empty stomach, at least 30 minutes before a meal, to enhance absorption. The maximum recommended dose should not exceed 40 mg/kg body weight per day. Regular monitoring of serum ferritin levels and liver function tests is essential to ensure the effectiveness and safety of the treatment.

Interactions

DEFRIJET may interact with several medications, which can affect its efficacy or increase the risk of side effects. Co-administration with other iron supplements is not recommended, as it may lead to increased iron levels in the body. Additionally, caution should be exercised when using DEFRIJET with drugs that are known to affect renal function or hepatic metabolism, such as non-steroidal anti-inflammatory drugs (NSAIDs) and certain antibiotics. It is advisable for patients to inform their healthcare provider of all medications they are currently taking to avoid potential interactions.

Precautions

Before starting treatment with DEFRIJET, a thorough medical history and assessment of the patient’s renal and hepatic function should be performed. Regular monitoring of blood counts, liver function tests, and renal function is essential during treatment. Patients should be advised to report any unusual symptoms, such as fever, sore throat, or bleeding, as these may indicate serious side effects. Special caution is warranted in elderly patients and those with pre-existing renal or hepatic conditions. Pregnant or breastfeeding women should discuss the risks and benefits of DEFRIJET with their healthcare provider prior to use.

Clinical Studies

Clinical studies have demonstrated the efficacy of DEFRIJET in reducing iron overload in patients with various conditions. In a multicenter trial, patients receiving DEFRIJET showed a significant reduction in serum ferritin levels compared to those receiving placebo. Long-term studies have also indicated that DEFRIJET effectively decreases the risk of complications associated with chronic iron overload, such as liver fibrosis and cardiac dysfunction. These findings support the use of DEFRIJET as a first-line treatment option for managing iron overload in at-risk populations.

Conclusion

DEFRIJET 250 MG is a valuable therapeutic option for patients suffering from iron overload due to chronic anemias or multiple blood transfusions. Its mechanism of action as a selective iron chelator allows for effective management of excess iron in the body, thereby reducing the risk of serious complications. While DEFRIJET is generally well-tolerated, it is essential for healthcare providers to monitor patients closely for potential side effects and interactions. With appropriate use and monitoring, DEFRIJET can significantly improve the quality of life for patients with iron overload conditions.